In this secondary study of an open-label , 28-week , randomized , controlled trial conducted between April 2009 and August 2011 , clinically stable patients with schizophrenia ( DSM-IV ) treated with risperidone or olanzapine were randomly assigned to the reduction group ( dose reduced by 50 % ) or maintenance group ( dose kept constant ) .